Factors Associated with Survival of Veterans with Gastrointestinal Neuroendocrine Tumors

Table 1

Demographic and baseline clinical characteristics of veterans with gastrointestinal neuroendocrine tumors (𝑛=1793).

Characteristic	𝑛 (%)	Deceased 𝑁=647	Not deceased 𝑁=1146
Age (years), mean (SD)	62.6 (11.0)	67.2 (11.1)	60.0 (10.0)
Gender
Male	1725 (96.3%)	635 (98.2%)	1090 (95.1%)
Female	67 (3.7%)	12 (1.9%)	55 (4.8%)
Race
White	1156 (65.5%)	452 (70.3%)	704 (62.8%)
Non-white	608 (34.5%)	191 (29.7%)	417 (37.2%)
Ethnicity
Hispanic	88 (4.9%)	22 (3.4%)	66 (5.8%)
Non-Hispanic	1705 (95.1%)	625 (96.6%)	1080 (94.2%)
Marital status
Married	893 (51.1%)	302 (48.6%)	591 (52.4%)
Not married	856 (48.9%)	319 (51.4%)	537 (48.6%)
GI NET location
Stomach	166 (9.3%)	71 (11.0%)	95 (8.3%)
Duodenum	186 (10.4%)	70 (10.8%)	116 (10.1%)
Small intestine	431 (24.0%)	229 (35.4%)	202 (17.6%)
Colon	336 (18.7%)	133 (20.6%)	203 (17.7%)
Rectum	674 (37.6%)	144 (22.3%)	530 (46.3%)
Cancer stage
In situ and localized	1106 (61.7%)	304 (47.0%)	802 (70.0%)
Regional	298 (16.6%)	131 (20.3%)	167 (14.6%)
Distant metastases	218 (12.2%)	136 (21.0%)	82 (7.2%)
Missing	171 (9.5%)	76 (11.8%)	95 (8.3%)
Tumor size (mm), mean (SD)	19.4 (26.4)	24.6 (31.8)	16.9 (23.0)
Treatment
Surgery	1309 (73.0%)	399 (61.7%)	910 (79.4%)
Radiation	21 (1.2%)	16 (2.5%)	5 (0.4%)
Chemotherapy	71 (4.0%)	45 (7.0%)	26 (2.3%)
Hormone	1(0.1%)	0 (0%)	1 (0.1%)
Biological response modifiers	26 (1.5%)	14 (2.2%)	12 (1.1%)
Year of diagnosis
1995–1999	363 (20.3%)	260 (40.2%)	103 (9.0%)
2000–2004	619 (34.5%)	262 (40.5%)	357 (31.2%)
2005–2009	811 (45.2%)	125 (19.3%)	686 (59.9%)

Missing data occurred as follows: gender (𝑛=1), race (𝑛=29), marital status (𝑛=44), tumor size (𝑛=818), surgery (𝑛=2), radiation (𝑛=5), chemotherapy (𝑛=4), hormone (𝑛=5), and biological response modifiers (𝑛=1).